A G Olsson

Summary

Country: Sweden

Publications

  1. pmc Recent advances in preventing cardiovascular disorders by managing lipid levels
    Anders G Olsson
    Department of Medicine and Health, Faculty of Health Sciences, Linkoping University, Linköping and Stockholm Heart Center Bergviksvägen 48, SE 167 63 Bromma Sweden
    F1000 Med Rep 2:66. 2010
  2. doi request reprint LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
    Anders G Olsson
    Department of Internal Medicine, University Hospital, Linkoping, Sweden
    Eur J Cardiovasc Prev Rehabil 18:262-9. 2011
  3. doi request reprint HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin
    A G Olsson
    Department of Medicine and Health, Faculty of Health Sciences, Linkoping University, Linkoping, Bergviksvägen 48, SE 176 63 Bromma, Sweden
    Nutr Metab Cardiovasc Dis 20:553-7. 2010
  4. ncbi request reprint Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
    Anders G Olsson
    Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
    Expert Opin Pharmacother 11:1715-26. 2010
  5. ncbi request reprint Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
    A G Olsson
    Department of Medicine and Care, University Hospital, Linkoping, Sweden
    Am J Cardiol 88:504-8. 2001
  6. ncbi request reprint A new statin: a new standard
    A G Olsson
    Clinical Research Center, University Hospital, Linkoping, Sweden
    Clin Cardiol 24:III18-23. 2001
  7. ncbi request reprint Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin
    A G Olsson
    Department of Medicine and Care, University Hospital, , Sweden
    Am J Cardiol 87:33B-36B. 2001
  8. ncbi request reprint Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial
    A G Olsson
    Hälsouniversitet Institutionen för Internmedicin, Linkoping, Sweden
    Clin Ther 23:45-61. 2001
  9. ncbi request reprint Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
    A G Olsson
    Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    Acta Physiol Scand 176:147-50. 2002
  10. ncbi request reprint Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia
    H M Blomqvist
    Division of Internal Medicine, Department of Medicine and Care, Clinical Research Center, Faculty of Health Sciences, Linkoping, Sweden
    Scand J Clin Lab Invest 63:513-9. 2003

Detail Information

Publications17

  1. pmc Recent advances in preventing cardiovascular disorders by managing lipid levels
    Anders G Olsson
    Department of Medicine and Health, Faculty of Health Sciences, Linkoping University, Linköping and Stockholm Heart Center Bergviksvägen 48, SE 167 63 Bromma Sweden
    F1000 Med Rep 2:66. 2010
    ..Trials of niacin/laropiprant (the AIM-HIGH and HPS2-THRIVE studies) and ezetimibe (the IMPROVE-IT study) are already under way...
  2. doi request reprint LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
    Anders G Olsson
    Department of Internal Medicine, University Hospital, Linkoping, Sweden
    Eur J Cardiovasc Prev Rehabil 18:262-9. 2011
    ..5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups...
  3. doi request reprint HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin
    A G Olsson
    Department of Medicine and Health, Faculty of Health Sciences, Linkoping University, Linkoping, Bergviksvägen 48, SE 176 63 Bromma, Sweden
    Nutr Metab Cardiovasc Dis 20:553-7. 2010
    ..Long-term interventional studies with hard endpoints of both therapies are ongoing. Also both drugs, when proven efficient and safe, are eagerly needed in the prevention of cardiovascular disease...
  4. ncbi request reprint Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
    Anders G Olsson
    Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
    Expert Opin Pharmacother 11:1715-26. 2010
    ..In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density lipoprotein (LDL)-cholesterol and lipoprotein(a) and has been named the broad-spectrum lipid drug...
  5. ncbi request reprint Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
    A G Olsson
    Department of Medicine and Care, University Hospital, Linkoping, Sweden
    Am J Cardiol 88:504-8. 2001
    ..Over 6 weeks, rosuvastatin produced large, rapid, dose-dependent LDL cholesterol reductions and was well tolerated in hypercholesterolemic patients...
  6. ncbi request reprint A new statin: a new standard
    A G Olsson
    Clinical Research Center, University Hospital, Linkoping, Sweden
    Clin Cardiol 24:III18-23. 2001
    ..Overall, these findings suggest that rosuvastatin is a promising new medication for the treatment of dyslipidemias...
  7. ncbi request reprint Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin
    A G Olsson
    Department of Medicine and Care, University Hospital, , Sweden
    Am J Cardiol 87:33B-36B. 2001
    ..5% reduction in LDL-C with each doubling of the rosuvastatin dose. Rosuvastatin treatment was well tolerated. Phase 3 clinical trials of this agent are under way...
  8. ncbi request reprint Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial
    A G Olsson
    Hälsouniversitet Institutionen för Internmedicin, Linkoping, Sweden
    Clin Ther 23:45-61. 2001
    ..A new extended-release (ER) formulation of fluvastatin 80 mg has been developed for once-daily treatment of primary hypercholesterolemia...
  9. ncbi request reprint Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
    A G Olsson
    Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    Acta Physiol Scand 176:147-50. 2002
    ..Statin treatment seems to be able to decrease this inflammatory response...
  10. ncbi request reprint Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia
    H M Blomqvist
    Division of Internal Medicine, Department of Medicine and Care, Clinical Research Center, Faculty of Health Sciences, Linkoping, Sweden
    Scand J Clin Lab Invest 63:513-9. 2003
    ....
  11. ncbi request reprint Impaired cortisol response to acute stressors in patients with coronary disease. Implications for inflammatory activity
    J Nijm
    Department of Medicine, Högland Hospital, Eksjo, and Department of Medicine and Care, Division of Cardiology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    J Intern Med 262:375-84. 2007
    ..We hypothesized that an altered hypothalamic-pituitary adrenal (HPA) axis activity was linked to a disinhibited inflammatory activity in patients with coronary artery disease (CAD)...
  12. ncbi request reprint Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment
    S Lind
    Department of Medicine and Care, Faculty of Health Sciences, Linkoping University, Stockholm, Sweden
    J Intern Med 256:406-12. 2004
    ..However, a phenotype very similar to FH may also be caused by defects in other genes like the genes for apolipoprotein (apo) B-100 or autosomal recessive hypercholesterolaemia (ARH)...
  13. ncbi request reprint The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus
    T Lindstrom
    Faculty of Health Sciences, Linkoping University, Sweden
    Diabet Med 16:820-6. 1999
    ..To study whether changes in endogenous insulin secretion at the same glycaemic control affect the plasma concentrations of lipoproteins in patients with Type 2 diabetes mellitus...
  14. ncbi request reprint The lower the better? Experiences from cardiovascular disease and stroke prevention
    A G Olsson
    Internal Medicine, IMV, Berzelius Science Park, University Hospital, Linkoping, Sweden
    Acta Neurol Scand Suppl 185:58-62. 2006
  15. ncbi request reprint Ultrasound determined carotid and femoral atherosclerosis in Lithuanian and Swedish men: the LiVicordia study
    M Kristenson
    Department of Health and Environment, Faculty of Health Sciences, Linkoping, Sweden
    Atherosclerosis 151:501-8. 2000
    ..32). These findings show that the higher coronary mortality noted in Lithuanian men goes together with a higher prevalence of early peripheral atherosclerosis...
  16. ncbi request reprint Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristics
    N E Nielsen
    Department of Cardiology, University Hospital, S 581 85 Linkoping, Sweden
    J Intern Med 247:43-52. 2000
    ....
  17. ncbi request reprint Low serum beta-carotene reflects immune activation in patients with coronary artery disease
    L Jonasson
    Department of Cardiology, Heart Center, University Hospital, S 581 85 Linkoping, Sweden
    Nutr Metab Cardiovasc Dis 13:120-5. 2003
    ..An immunomodulatory effect of antioxidants has been proposed. The aim of the study was to investigate whether an increased immune response in CAD patients was associated with suppressed circulating levels of antioxidant vitamins...